Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: results from the TEAMIIA study (BOOG2006-04)

Abstract Purpose In the adjuvant setting, specific adverse events(AEs) such as vasomotor symptoms (VMS) and musculoskeletal AEs are associated with relapse-free survival in aromatase inhibitor(AI)-treated patients. In the neoadjuvant setting, specific AEs may be associated with tumor response to AIs...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2017-04, Vol.43 (4), p.619-624
Main Authors: Fontein, Duveken B.Y, Charehbili, Ayoub, Nortier, Johan W.R, Putter, H, Kranenbarg, Elma Meershoek-Klein, Kroep, Judith R, Linn, Sabine C, van de Velde, Cornelis J.H
Format: Article
Language:English
Subjects:
Adverse events
Aged
Aged, 80 and over
Androstadienes - adverse effects
Aromatase inhibitors
Aromatase Inhibitors - adverse effects
Arthralgia - chemically induced
Arthritis - chemically induced
Breast cancer
Breast Neoplasms - diagnostic imaging
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Carcinoma, Ductal, Breast - diagnostic imaging
Carcinoma, Ductal, Breast - drug therapy
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Lobular - diagnostic imaging
Carcinoma, Lobular - drug therapy
Carcinoma, Lobular - metabolism
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Hot Flashes - chemically induced
Hot flushes
Humans
Joint Diseases - chemically induced
Logistic Models
Magnetic Resonance Imaging
Mammography
Mastectomy
Middle Aged
Multivariate Analysis
Musculoskeletal Diseases - chemically induced
Myalgia - chemically induced
Neoadjuvant Therapy
Odds Ratio
Osteoporosis - chemically induced
Postmenopause
Prognosis
Receptors, Estrogen - metabolism
Surgery
Treatment Outcome
Ultrasonography, Mammary
Vasomotor System
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Purpose In the adjuvant setting, specific adverse events(AEs) such as vasomotor symptoms (VMS) and musculoskeletal AEs are associated with relapse-free survival in aromatase inhibitor(AI)-treated patients. In the neoadjuvant setting, specific AEs may be associated with tumor response to AIs as well. Methods Between 2007 and 2012, 107 patients participated in the prospective TEAMIIA trial, a prospective, phase II trial investigating 6 months of neoadjuvant exemestane in patients with strongly ER-positive breast cancer. Radiological response (≥30% decrease in tumor size) was studied in relation to VMSs and MSAEs. Pearson’s Chi-Square tests and multivariate logistic regression analyses were used to evaluate of statistical significance (p
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2016.07.146